SCHEMBL4804983

SCHEMBL4804983

Cc1cn([C@H]2C[C@@H](O)[C@@H](COO)O2)c(=O)[nH]c1=O

nearest known ligand 0.72

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.68
TK1 P04183 3/20 0.65
BCHE P06276 1/20 0.62
TYMS P04818 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4809523 1.00 POLB (0.68) POLBTK1BCHETYMS
SCHEMBL6379335 1.00 POLB (0.68) POLBTK1BCHETYMS
SCHEMBL19101672 0.91 POLB (0.66) POLBTK1BCHETYMS
SCHEMBL6046227 0.91 POLB (0.66) POLBTK1BCHETYMS
SCHEMBL12918450 0.91 TK1 (0.69) POLBTK1BCHETYMS
SCHEMBL17236294 0.91 TK1 (0.69) POLBTK1BCHETYMS
SCHEMBL135209 0.91 TK1 (0.69) POLBTK1BCHETYMS
SCHEMBL4198253 0.91 TK1 (0.69) POLBTK1BCHETYMS
SCHEMBL22943603 0.91 TK1 (0.69) POLBTK1BCHETYMS
SCHEMBL17232081 0.91 TK1 (0.69) POLBTK1BCHETYMS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005058247-A2 METHOD FOR PREPARING RADIOLABELED THYMIDINE HAVING LOW CHROMOPHORIC BYPRODUCTS MOLECULAR TECHNOLOGIES, INC. (US) 2005-06-30 WO claimed
US-20050131223-A1 Method for preparing radiolabeled thymidine having low chromophoric byproducts CTI PET SYSTEMS, INC. 2005-06-16 US claimed
US-7419653-B2 Method for preparing radiolabeled thymidine having low chromophoric byproducts SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2008-09-02 US disclosed
US-20070077198-A1 Method for preparing radiolabeled thymidine having low chromophoric byproducts WALSH JOSEPH C 2007-04-05 US disclosed
US-7160537-B2 Method for preparing radiolabeled thymidine having low chromophoric byproducts SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2007-01-09 US disclosed
WO-2005058247-A2 METHOD FOR PREPARING RADIOLABELED THYMIDINE HAVING LOW CHROMOPHORIC BYPRODUCTS MOLECULAR TECHNOLOGIES, INC. (US) 2005-06-30 WO disclosed
US-20050131223-A1 Method for preparing radiolabeled thymidine having low chromophoric byproducts CTI PET SYSTEMS, INC. 2005-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050131223-A1 Method for preparing radiolabeled thymidine having low chromophoric byproducts TYMP, TYMS, FLT1 POLB 155/4885TK1 5/4885BCHE 247/4885
US-20070077198-A1 Method for preparing radiolabeled thymidine having low chromophoric byproducts TYMP, TYMS, FLT1 POLB 155/4885TK1 5/4885BCHE 247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.